Drugmaker CEOs skeptical of AI disease cure claims

Pharmaceutical executives question Silicon Valley's promises that AI will cure diseases.

A Wall Street Journal report details skepticism among drugmaker CEOs toward AI's potential to transform healthcare and drug discovery. Tech leaders from Silicon Valley continue to make bold claims about AI solving medical problems, but industry executives are not convinced. The piece highlights the divide between AI hype and practical adoption in the pharmaceutical sector.